MMV167

MMV167

Translational
-
Preclinical
(OHSU USF)
Asexual blood stages
Causal prophylaxis
Product vision
  • Prophylaxis
MOA

  • Pro-drug of MMV055 - inhibition of parasite cytochrome bc1 (Qi site)
Key features
  • Same target but different binding site to atovaquone
  • No cross resistance with atovaquone-resistant parasites
  • Targets actively replicating parasites in the liver, bloodstream, and vector stages of infection 
  • Potential partner for MMV371 in a long-acting injectable product
Challenges
  • Feasibility of intra-muscular formulation
  • Safety inherent to prophylaxis indication
Status

  • Preclinical development
Next milestone
  • Formulation development
  • Complete toxicology programme
Previously
  • Discovered at Oregon Health and Sciences University (OHSU, Michael Riscoe team) in collaboration with the Department of Veterans Affairs.
  • ELQ 331
Project Director
  • Dr Benoît Bestgen